Table 1.
Patient baseline characteristics
| Characteristic | TXA (N = 49) | TXA placebo (N = 51) | Rosuvastatin (N = 18) | Rosuvastatin placebo (N = 16) |
|---|---|---|---|---|
| Mean age ± SD, years | 70.0 ± 8.2 | 69.5 ± 8.9 | 68.4 ± 9.1 | 68.4 ± 10.6 |
| Male sex, n (%) | 26 (53.1) | 28 (54.9) | 12 (66.7) | 6 (37.5) |
| Eligibility criteria met, n (%) | ||||
| Age ≥ 45 years | 49 (100) | 51 (100) | 18 (100) | 16 (100) |
| Preoperative NT-pro-BNP > 100 ng/mL | 5 (10.2) | 5 (9.8) | 1 (5.6) | 6 (37.5) |
| Patients fulfilling at least one or more of the following 5 criteria | 48 (98.0) | 50 (98.0) | 18 (100) | 14 (87.5) |
| 1. History of coronary disease | 15 (30.6) | 14 (27.5) | 2 (11.1) | 1 (6.3) |
| 2. History of peripheral vascular disease | 7 (14.3) | 8 (15.7) | 5 (27.8) | 3 (18.8) |
| 3. History of stroke | 2 (4.1) | 1 (2.0) | 0 (0.0) | 1 (6.3) |
| 4. Undergoing major vascular surgery | 2 (4.1) | 3 (5.9) | 1 (5.6) | 1 (6.3) |
| 5. Patients fulfilling any 3 of the following risk factors | 35 (71.4) | 35 (68.6) | 13 (72.2) | 12 (75.0) |
| Undergoing major surgery | 29 (59.2) | 31 (60.8) | 14 (77.8) | 12 (75.0) |
| History of congestive heart failure | 1 (2.0) | 3 (5.9) | 1 (5.6) | 0 (0.0) |
| History of transient ischemic attack | 2 (4.1) | 4 (7.8) | 0 (0.0) | 0 (0.0) |
| Diabetes and currently taking an oral hypoglycemic | 19 (38.8) | 16 (31.4) | 3 (16.7) | 4 (25.0) |
| Age ≥ 70 years | 28 (57.1) | 31 (60.8) | 11 (61.1) | 8 (50.0) |
| Hypertension | 41 (83.7) | 46 (90.2) | 15 (83.3) | 14 (87.5) |
| Serum creatinine > 175 μmol/L | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| History of smoking within 2 years of surgery | 12 (24.5) | 14 (27.5) | 6 (33.3) | 5 (31.3) |
| Undergoing emergent/urgent surgery | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Mean preoperative hemoglobin ± SD, g/L | 134.7 ± 15.7 | 130.0 ± 14.1 | 135.3 ± 17.5 | 137.4 ± 13.3 |
| Serum creatinine (μmol/L) | 88.3 ± 29.2 | 90.1 ± 27.6 | 77.7 ± 16.2 | 80.4 ± 23.9 |
| Mean time from randomization to start of surgery ± SDa, hours | 29.8 ± 18.6 | 32.2 ± 22.0 | 29.7 ± 19.9 | 31.4 ± 21.8 |
| Time from randomization to start of surgery, n (%) | ||||
| ≤ 24 h | 21 (42.9) | 24 (47.1) | 9 (50.0) | 8 (50.0) |
| 24–48 h | 23 (46.9) | 18 (35.3) | 6 (33.3) | 6 (37.5) |
| > 48 hb | 5 (10.2) | 8 (16.0) | 3 (16.7) | 2 (12.5) |
TXA tranexamic acid, SD standard deviation
aPercentages are reported among the total of patients, i.e., the denominator includes also patients in which NT-proBNP was not measured
bAfter excluding from the calculation a patient for whom surgery was canceled after randomization and postponed to 64 days later